Oct. 4 at 7:19 PM
$ONCY Pelareorep acts as a "backbone" immunotherapeutic that enhances the effectiveness of other I/O therapies through several synergistic mechanisms:
1. Creates an inflamed tumor phenotype and remodels the tumor microenvironment (TME) that is conducive to an immune attack, effectively turning "cold" tumors "hot".
2. Boosts immune cell infiltration: The inflammatory signals released by pelareorep infection recruit immune cells, including T-cells and natural killer (NK) cells, into the TME. Studies have shown that pelareorep significantly increases tumor-infiltrating lymphocytes (TILs), which is crucial for a robust anti-tumor response.
3. "Primes" the immune system and educates the adaptive immune system: thereby turning cold tumnors "hot".
4. Upregulates PD-L1: an ideal target for the addition of ICIs.
5. Synergy with checkpoint inhibitors: By pairing pelareorep with an ICI, the "brakes are released" on T-cells' ability to kill tumor cells, because of their activation by pelareorep
